海思科：HSK47388片新适应症获药物临床试验批准

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its self-developed drug HSK47388, aimed at treating autoimmune diseases [1] Group 1: Drug Development - HSK47388 is an oral, potent, and highly selective drug [1] - Preclinical studies have shown significant efficacy in a rat model of colitis [1] - The drug demonstrates good tolerability and a large safety window [1] Group 2: Market Implications - This application represents a new indication for HSK47388 in the field of autoimmune diseases [1] - The drug is expected to provide a new treatment option for patients suffering from autoimmune diseases [1]